Company news
Rein Therapeutics, Inc. news in 2024
Rein Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 13, 2024
Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
November 12, 2024
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma
October 30, 2024
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis
October 11, 2024
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
September 22, 2024
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
August 13, 2024
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
July 29, 2024
Aileron Therapeutics to be Included in the Russell Microcap® Index
June 30, 2024
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 14, 2024
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
May 5, 2024
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
May 2, 2024
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
April 30, 2024
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
April 30, 2024
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 14, 2024
Aileron Therapeutics Announces CEO Transition
March 11, 2024
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
February 14, 2024
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
January 31, 2024